Clinical trial
Homoharringtonine and Interferon Alfa in Treating Patients With Chronic…
NCT00002574 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00002574 |
|---|---|
| Title | Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia |
| Official title | PHASE II STUDY OF SIMULTANEOUS HOMOHARRINGTONINE (NSC 141633) AND ALPHA INTERFERON (IFN-A) THERAPY IN CHRONIC MYELOGENOUS LEUKEMIA (CML) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | recombinant interferon alfa, omacetaxine mepesuccinate |
| Enrollment | 87 |
| Start date | Sep 1, 1994 |
| Primary completion | Jun 1, 2001 |
| First posted | Aug 10, 2004 |
| Last update posted | Feb 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: